An open-label, single-dose, randomized, parallel-group study of the safety and relative bioavailability of topical sildenafil cream vs oral sildenafil in healthy male adults Authors: Katherine Cornell, Isabella Johnson, Andrea Thurman, David Friend Published: 2026 ABSTRACT AbstractIntroductionOral phosphodiesterase-5 (PDE5) inhibitors are commonly prescribed for erectile dysfunction (ED), but have limiting side effects, particularly for men with serious cardiovascular disease. Topical sildenafil cream was developed based on the hypothesis that local genital application would result in less systemic exposure and fewer side effects compared to oral sildenafil citrate. The objective of this study was to describe the systemic pharmacokinetics (PK) and safety of topical sildenafil cream 3.6% in healthy men, applied to the penis with and without male condom use, compared to oral sildenafil.MethodsPhase 1, open-label, single-dose, randomized, parallel-group design. Participants were randomized 1:1:1:1:1 to 36 mg of sildenafil in 1 g of cream or 71 mg of sildenafil in 2 g of cream self-applied to the penile skin with or without male condom use vs a 50 mg oral dose of sildenafil. Blood and orthostatic vital signs were taken prior to dosing and up to 32 hours post dosing. Safety was assessed by treatment emergent adverse events (TEAEs) and physical exam. Single dose PK parameters for plasma sildenafil and its active metabolite, N-desmethyl sildenafil were calculated.ResultsSixty-two men received study medication. All TEAEs (n = 14) were mild. Half of the TEAEs (7/14, 50%), including headache (n = 4) and flushing (n = 2), resulted from oral dosing. The mean maximum plasma concentration (Cmax) of sildenafil after topical application (all 4 dosing groups) ranged from 969 to 1274 pg/mL, compared to 238 000 pg/mL with oral administration. Dose proportionality assessments using the geometric means of Cmax and systemic exposure (AUClast) and total amount of drug absorbed over the entire elimination period (AUCinf) indicated that the geometric means of all 3 PK parameter estimates were similar with a 2-fold increase in dose, indicating a less than dose-proportional increase. Similar results were observed with or without condom use in the topical application groups. Compared to oral administration, the relative bioavailability of sildenafil after topical application ranged from 2.55% to 3.20%. Similar results were observed for the N-desmethyl sildenafil.DiscussionThis safety and PK study provides early data on the comparison of Sildenafil cream topical dosing to the oral dosing referent. Topically applied Sildenafil Cream was safe and well tolerated by healthy men. Topical sildenafil cream use was associated with lower systemic exposure compared to oral sildenafil use.Keywords: erectile dysfunction, topical sildenafil, safety, pharmacokinetics Introduction Erectile dysfunction (ED), a sexual dysfunction affecting an estimated 25% of men aged 18-34 years old and over 60% of men aged 60-75 years old,1 is characterized by the inability to develop or maintain an erection of the penis during sexual performance. Phosphodiesterase type-5 (PDE5) inhibitors are considered the standard of care in first-line ED treatment but have limiting side effects.2 Oral PDE5 inhibitors, such as sildenafil, have been administered as treatments for ED since FDA approval in 1998 and have made a significant impact in sexual well-being in the lives of their users, but have limiting side effects.2 Sildenafil has systemic vasodilatory properties that result in decreased supine blood pressure (BP) in healthy individuals.3 In patients who do not have medical contraindications, mild and temporary side effects include vasodilation, headache, flushing, upset stomach, and nausea.4 Rare, more serious side effects (including myocardial infarction or death) have been reported in patients requiring intake of organic nitrates while on oral sildenafil and, as such, oral sildenafil must never be taken by men who are taking medicines that contain nitrates of any kind, at any time.3 To minimize systemic side effects, our team developed a topical preparation of sildenafil, which has been tested in both premenopausal and postmenopausal women with female sexual arousal disorder (FSAD), the female equivalent of ED.5,6 As expected, topical application of sildenafil in women results in plasma concentrations that are orders of magnitude lower than those observed with oral administration and result in a much more acceptable side effect and safety profile,6 compared to other studies of oral dosing of sildenafil in women with sexual dysfunction.7–10 This Phase 1 begins the testing of topical sildenafil cream in healthy adult men without ED. Specifically, this study tests the following hypotheses: first, is a single topical dose of sildenafil cream safe for healthy adult men? Second, are the systemic absorption and bioavailability of sildenafil and its active metabolite, N-desmethyl sildenafil, significantly different after a single topical dose of sildenafil cream compared to a single oral dose? Finally, we tested the hypothesis “does condom use alter systemic pharmacokinetics of sildenafil and N-desmethyl sildenafil”? Methods Study population The clinical trial was conducted at 1 site in the United States and was approved by the Institutional Review Board and registered at ClinicalTrials.gov. All volunteers provided written informed consent prior to the performance of any study procedures. The schedule of evaluations is displayed in Supplemental Table 1. In brief, healthy men able to achieve a successful erection between the ages of 18-55 years inclusive were enrolled. At screening, their resting supine systolic and diastolic BP had to be between 90-140 and 50-90 mm Hg, respectively. Participants had to be healthy as determined by the Investigator based on medical history, physical examination, clinical laboratory tests, vital sign measurements, and have a normal 12-lead electrocardiogram (ECG). Finally, men had to be nonsmokers or be abstinent from tobacco products for the past 6 months. Men were excluded if they had a self-reported history of ED or a prostatectomy; any surgical or medical condition that could interfere with the absorption, distribution, metabolism, or excretion of the study product; a history of myocardial infarction, stroke, or life-threatening arrhythmia within 6 months prior to study Day 1; history of coronary disease causing angina; those with retinitis pigmentosa, sickle cell anemia or related anemias, even if they felt clinically well at the time of screening; anatomical deformations of the penis such as angulation, cavernosal fibrosis or Peyronie’s disease; history of postural orthostatic hypotension or postural orthostatic hypotension present at the screening visit; history of alcoholism, alcohol or drug abuse within 1 year. Finally, participants were excluded if they had any skin breaks, irritation, or lesions present in the area to which the cream will be applied, assessed at screening. Men returned within 28 days of screening to confirm they were eligible for the study. They were instructed to fast for 8 hours prior to coming to the research center. They were randomized into 1 of 5 groups and admitted to the research center for overnight blood draws and safety assessments. Blood and vital signs were obtained prior to treatment and after treatment. After 4 hours of assessments, participants were able to eat lunch. Participants in the sildenafil cream groups were asked to take a shower approximately 12-hours after dosing. On study Day 2, once PK sample collection and other study procedures were completed, the participants received a final symptom-directed physician exam and were queried about TEAEs. Participants were then discharged from the center and contacted 7-10 days later for a final exit interview. Randomization Participants were randomized in a 1:1:1:1:1 manner in the following groups: Group A: 36 mg sildenafil in 1 g of cream self-applied to test area without male condom use; Group B: 36 mg sildenafil in 1 g of cream self-applied to test area with male condom use; Group C: 71 mg sildenafil in 2 g of cream self-applied to the test area without condom use; Group D: 71 mg sildenafil in 2 g of cream self-applied to the test area with a male condom; Group E: Single oral 50 mg sildenafil dose. There were no allocation errors. Study product Oral 50 mg sildenafil tablets were purchased from the pharmacy. Sildenafil cream contained 5% weight/weight of sildenafil citrate (3.6% sildenafil) and was a white cream (1 or 2 g) which absorbed into the skin within 1-2 minutes. Investigational product (IP) was stored at room temperature (20-25 °C) in a secure, temperature- and humidity-monitored area. Study product dosing The pharmacist allocated the appropriate IP to each participant. Men receiving the cream applied and massaged the cream into the shaft and glans of their non-erect penis for approximately 3 minutes. They were then provided with visual stimulation materials to allow for an erection and could use manual self-manipulation if necessary. Participants assigned to condom use applied a non-lubricated condom to the penis once erection was achieved and the condom was left on for at least 10 minutes. Men assigned to the 50 mg oral dose of sildenafil took the tablet with 8 ounces of water. Participants did not shower or remove the cream after application during their overnight stay at the research facility. Safety assessments Participants recorded treatment-emergent adverse events (TEAEs) in their diary. Vital signs, orthostatic vital signs, and symptoms of hypotension were monitored. Supine vital signs (BP and pulse) were measured pre-dose, at 15, 30, and 45 minutes after dosing, and at 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 24 hours after dosing. Additional standing (orthostatic supine to standing) vital signs were measured pre-dose and at 2, 4, 6, 8, and 24 hours after dosing. Additional safety assessments included observation of the IP application site, safety laboratories, ECG, and physical exams. All AEs were coded using Medical Dictionary for Regulatory Activities (MedDRA) version 16.1. Coding of AEs was done to the lowest level term (LLT); reporting was done by MedDRA preferred term. Pharmacokinetic (PK) analyses A total of 20 blood samples were collected from each participant to assess the sildenafil and the N-desmethyl sildenafil metabolite plasma concentrations. Blood samples were collected pre-dose (within 15 minutes of dosing) on Day 1; at 15, 30, and 45 minutes after dosing; and at 1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 12, 18, 24, 28, and 32 hours after dosing. A 10 mL blood sample was collected at each PK time point in appropriately labeled, dipotassium ethylenediaminetetraacetic acid (K2EDTA) vacutainer tubes (lavender top). The tubes were chilled on wet ice or in a refrigerator prior to collection. Immediately after blood collection, the blood tubes were inverted several times and kept on wet ice until centrifuged. Within 30 minutes of blood collection, the samples were separated by centrifugation for 15 minutes at 1200 to 1500 × g at 4 °C. Processing was completed on wet ice. The resultant plasma was transferred in approximately equal volumes into 2 appropriately labeled polypropylene tubes for PK assay and was stored upright (within 1 hour of the blood sampling time) at -80 °C (± 15 °C) until the time of shipment. The following single dose PK parameters were calculated based on randomization group: Cmax the maximum observed concentration; Tmax or time of the maximum observed concentration (Cmax); AUClast or area under the concentration-time curve, calculated using linear trapezoidal summation from time zero to time last, where time last was the time of the last measurable concentration (Ct); AUC0-t or the area under the concentration-time curve from time zero to time t, where time t was the time of the last measurable concentration that was common to all treatment groups; AUCinf was the area under the concentration vs time curve from time zero to infinity, (AUC0-inf = AUC0-t + Ct/Kel,) where Kel was the apparent terminal elimination rate constant and t1/2 was the apparent terminal elimination half-life. Kel was calculated by linear regression of the apparent terminal linear portion of the log concentration vs time curve. V/F was the apparent volume of distribution (where F=Bioavailability) and CL/F was the apparent clearance, calculated for sildenafil as Dose/AUCinf (where F=Bioavailability). PK parameters were estimated for sildenafil and its metabolite using non-compartmental analysis (NCA) within Phoenix WinNonlin v6.3 program. Sample size and statistical analysis The sample size of this study was not designed to statistically compare safety or PK endpoints between the 5 dosing groups and is therefore descriptive in nature. The primary analysis was performed in the PK evaluable population, which consisted of participants who provided an adequate number of blood samples (missing no more than 1 sample collection time point) to accurately derive the area under the plasma concentration-time profile used to determine the relative bioavailability of sildenafil. The safety analysis population consisted of all men who applied IP at least once during the study, and therefore TEAEs were reported. Results Participant demographics and disposition The first participant was screened in October 2013 and the last participant visit was in November 2013. A total of 62 men underwent informed consent. Table 1 shows the demographics of the study population by treatment group. Most of the men were Hispanic White and had a mean age of 41 years. Two participants were discontinued from the study after application of sildenafil cream as they were unable to achieve an erection. Therefore, these 2 men were included in the safety analysis, but were excluded from the PK evaluable population because they did not provide a prespecified number of plasma samples. Of the 62 participants enrolled in the study, all received dosing based on randomized dose group assignments. Table 1Demographics and baseline characteristics – safety population.Group AGroup BGroup CGroup DGroup ETotal36 mg sildenafil in 1 gm cream without occlusion36 mg sildenafil in 1 gm cream with occlusion71 mg sildenafil in 2 gm cream without occlusion71 mg sildenafil in 2 gm cream with occlusion50 mg oral sildenafil Total number of subjects Statistic 121312131262 Age (years) Mean (SD) 36.5 (10.8)35.9 (7.9)42.1 (7.3)42.9 (10.9)42.4 (8.8)40.0 (9.5) Range (min, max) 21.6,54.126.2,51.625.1,51.624.6,54.924.2,51.721.6,54.9 Ethnicity Hispanic or Latino, n (%) 9 (75.0)12 (92.3)11 (91.7)10 (76.9)10 (83.3)52 (83.9) Not Hispanic or Latino, n (%) 3 (25.0)1 (7.7)1 (8.3)3 (23.1)2 (16.7)10 (16.1) Race Black or African American, n (%) 3 (25.0)2 (15.4)0 (0)2 (15.4)1 (8.3)8 (12.9) White, n (%) 9 (75.0)11 (84.6)12 (100.0)11 (84.6)11 (91.7)54 (87.1) BMI (kg/m 2 ) Mean (SD) 26.5 (3.5)27.1 (2.1)26.1 (3.7)26.7 (2.3)25.4 (2.8)26.4 (2.9) Range (min, max) 18.3,30.023.0,30.019.3,29.822.6,30.018.8,28.718.3,30.0 Demographics and baseline characteristics – safety population. Safety data Table 2 displays the 14 mild TEAEs that were reported by 12 of the 62 men. All of the TEAEs were considered to be related to either study drug or study procedures; all were mild and resolved without sequelae. Seven of the 14 TEAEs reported during this study were experienced by 5 men in oral dosing group, with 4 of these 7 TEAEs reported as headache, which was considered related to the study treatment. One participant in each treatment arm experienced an event of asymptomatic postural orthostatic tachycardia, defined by the standing heart rate increasing by more than 20 beats per minute. There were no severe AEs, SAEs, or deaths during this study. There were no abnormal physical exam findings and no discontinuations due to TEAEs during this study. There were no laboratory abnormalities that were considered to be clinically meaningful. Table 2Summary of treatment emergent adverse events by meddra coded terms – safety population.MedDRA system organ class MedDRA preferred term version 16.1Group A 36 mg sildenafil in 1 gm cream without condom use N (%)Group B 36 mg sildenafil in 1 gm cream with condom use N (%)Group C 71 mg sildenafil in 2 gm cream without condom use N (%)Group D 71 mg sildenafil in 2 gm cream with condom use N (%)Group E 50 mg oral sildenafilTotal (n = 62), n (%)Total number of mild TEAEs1321714Number of subjects with at least one adverse event1 (8.3)3 (23.1)2 (16.7)1 (7.7)5 (41.7)12 (19.4)Cardiac disordersAsymptomatic postural orthostatic tachycardia1 (8.3)1 (7.7)1 (8.3)1 (7.7)1 (8.3)5 (8.1)General disorders and administration site conditionsApplication site pruritus02 (15.4)0002 (3.2)Nervous system disordersHeadache001 (8.3)04 (33.3)5 (8.1)Vascular disordersFlushing00002 (16.7)2 (3.2) Summary of treatment emergent adverse events by meddra coded terms – safety population. Plasma PK data Table 3 and Figure 1 show the single-dose plasma PK parameters for Sildenafil. The mean Tmax values ranged from 12.58 to 15.67 hours and were greater than the mean Tmax following oral administration (1.00 hour). The mean Cmax for sildenafil following topical application ranged from 969 to 1274 pg/mL. The mean AUClast for sildenafil following topical application ranged from 20 112 to 22 772 hr*pg/mL. The mean Kel values for sildenafil following topical application ranged from 0.08 to 0.12 hr-1 and the mean t1/2 values ranged from 6.48 to 12.28 hours. The mean apparent clearance (Cl/F) estimates for sildenafil following topical application ranged from 2386 to 6815 L/hr, and the mean volume of distribution (V/F) estimates ranged from 21 946 to 68 500 L. The sildenafil Cl/F and V/F following oral administration (Group E) was much lower than the corresponding estimates following topical application, implying a much higher bioavailability (F) following oral administration. Dose proportionality assessment using the geometric means of the PK parameter estimates, Cmax, AUClast and AUCinf, indicated that the geometric means of all 3 PK parameter estimates were similar with a 2-fold increase in dose, indicating a less than dose proportional increase for all 3 PK parameter estimates. Similar results were seen in both the with and without condom use groups. This observation points toward a potential saturable absorption from the topical application site but may also reflect interindividual variability. The PK parameters for n-desmethyl sildenafil (Supplemental Table 2) show a similar trend as those mentioned above for sildenafil. Table 3Single dose plasma pharmacokinetic parameters of sildenafil.TreatmentTmax (hours)Cmax (pg/mL)AUC last (hr a pg/mL)Kel (1/hours) N Mean% CV N Mean% CV N Mean% CV N Mean% CVSildenafilGroup A 36 mg. w/o occlusion1214.7540.17121270.7562.031220904.5938.08100.1227.52Group B 36 mg w/occlusion1215.0051.9512969.0055.521220112.4751.7090.0853.47Group C 71 mg w/o occlusion1215.6739.10121274.0035.661222772.5332.7290.1131.48Group D 71 mg w/occlusion1212.5843.19121249.3376.971221412.5369.71110.1126.00Group E 50 mg oral121.0033.7112238000.0044.3212741572.9244.12120.1622.08 Treatment T ½ (hours) AUCinf (hr a pg/mL) a Cl/F (L/hr) a V/F a (L) N Mean % CV N Mean % CV N Mean % CV N Mean % CV SildenafilGroup A 36 mg. w/o occlusion106.4832.42922998.3637.9792482.4139.51921946.1954.50Group B 36 mg w/occlusion912.2859.28424024.6940.4342386.2242.66422873.3564.42Group C 71 mg w/o occlusion97.3647.28722172.5733.3575015.9936.95742315.6541.27Group D 71 mg w/occlusion116.5431.661122192.6470.85116815.0566.531168499.8380.90Group E 50 mg oral124.5724.3012744556.7744.151282.4949.4812574.7771.51Tmax = Time to maximum plasma concentration.Cmax = Maximum plasma concentration.AUClast = Area under the concentration time cure where the last timepoint is the last measureable concentration.Kel = Apparent terminal elimination rate.T½ = Apparent terminal elimination half life.AUCinf = Area under the concentration vs time curve from time zero to infinity.Cl/F = Apparent clearance.V/F = Apparent volume of distribution. aOnly subjects with extrapolation % for AUCinf ≤ 20% were included in PK summary statistics for AUCinf, V/F and Cl/F. Single dose plasma pharmacokinetic parameters of sildenafil. Tmax = Time to maximum plasma concentration. Cmax = Maximum plasma concentration. AUClast = Area under the concentration time cure where the last timepoint is the last measureable concentration. Kel = Apparent terminal elimination rate. T½ = Apparent terminal elimination half life. AUCinf = Area under the concentration vs time curve from time zero to infinity. Cl/F = Apparent clearance. V/F = Apparent volume of distribution. aOnly subjects with extrapolation % for AUCinf ≤ 20% were included in PK summary statistics for AUCinf, V/F and Cl/F. Plasma sildenafil concentration vs time. Bioavailability data The relative bioavailability assessment, shown in Table 4, demonstrated a relative bioavailability of sildenafil after topical application in groups A-D, in the range of 2.55%-3.20%, suggesting a much lower systemic exposure following a topical application as compared to the reference oral tablet administration. The relative bioavailability was slightly lower when the topical formulation was applied followed by a male condom compared to the without condom application (9% lower in Group B vs A and 20% lower in Group D vs C) and was similar at both the dose levels of sildenafil [36 mg (Group A and B) vs 71 mg (Group C and D)], suggesting a possible saturable absorption mechanism at the application site, although this may also reflect interindividual variability. Similar results were observed for the n-desmethyl sildenafil metabolite with the relative bioavailability ratio (%) in the range of 0.48%-0.77% as compared to the metabolite exposure following reference oral tablet administration (Table 4). Table 4Relative bioavailability of sildenafil and its metabolite n-desmethyl sildenafil in topical sildenafil cream as compared to the sildenafil oral tablet.AnalyteTest groupReference groupTest LSM aReference LSM bDiff (Test LSM – Ref LSM)Test geometric LSM cReference geometric LSM dRatio % e90% Ci f lower90% Ci f upperSildenafilAE9.8813.42-3.5419525.47671653.30 2.91 2.064.11BE9.7913.42-3.6317819.51671653.30 2.65 1.883.75CE9.9813.42-3.4421522.25671653.30 3.20 2.274.53DE9.7513.42-3.6717107.27671653.30 2.55 1.803.60N-desmethyl sildenafilAE6.3511.68-5.33570.87117760.88 0.48 0.231.02BE6.4111.68-5.27608.21117760.88 0.52 0.241.11CE6.8211.68-4.86912.19117760.88 0.77 0.371.61DE6.5811.68-5.09721.87117760.88 0.61 0.291.29 aTest LSM: Least square mean of the natural log transformed AUClast (hr*pg/mL) values for Test formulation (Groups A-D). bRef LSM: Least square mean of the natural log transformed AUClast (hr*pg/mL) values for the reference formulation (Group E). cTest Geometric LSM: Antilog of Test LSM or geometric mean of AUClast (hr*pg/mL) values for the Test formulation (Group A - D). dReference Geometric LSM: Antilog of Ref LSM or geometric mean of AUClast (hr*pg/mL) values for the Reference formulation (Group E). eRatio % = % Bioavailability of test relative to the reference = [(Test Geometric LSM/Reference Geometric LSM)*100]. fCI: confidence interval around the ratio % Relative bioavailability of sildenafil and its metabolite n-desmethyl sildenafil in topical sildenafil cream as compared to the sildenafil oral tablet. aTest LSM: Least square mean of the natural log transformed AUClast (hr*pg/mL) values for Test formulation (Groups A-D). bRef LSM: Least square mean of the natural log transformed AUClast (hr*pg/mL) values for the reference formulation (Group E). cTest Geometric LSM: Antilog of Test LSM or geometric mean of AUClast (hr*pg/mL) values for the Test formulation (Group A - D). dReference Geometric LSM: Antilog of Ref LSM or geometric mean of AUClast (hr*pg/mL) values for the Reference formulation (Group E). eRatio % = % Bioavailability of test relative to the reference = [(Test Geometric LSM/Reference Geometric LSM)*100]. fCI: confidence interval around the ratio % Discussion Topical sildenafil cream 3.6% was safe and well tolerated by healthy men. The TEAEs in the study reflected known side effects of sildenafil (headache and flushing) and were seen more commonly with oral dosing. Asymptomatic postural tachycardia was observed in 1 participant in all 5 dosing groups. Of note, the elevation in heart rate, upon standing, was not associated with any changes in BP, and importantly, none of the participants had associated clinical symptoms of dizziness, vertigo, nausea or syncope. Among the 5 participants who exhibited postural tachycardia (as defined by the protocol of an elevation in heart rate of over 20 beats per minute) it occurred at either the 4-hour assessment for 2 participants and at the 8- hour assessment for the remaining 3 men, but not at other times when orthostatic vitals were taken. In an abundance of caution, the research site deemed the tachycardia as postural orthostatic tachycardia, related to the study drug. The mean Cmax of plasma sildenafil was approximately 187 times lower following topical application of 36 mg of sildenafil compared to oral administration (Groups A and B vs E). Sildenafil systemic exposure (AUClast and AUCinf) were 35-fold and 32-fold lower, respectively, following topical application of 36 mg compared to oral administration of 50 mg. The mean Cmax and AUClast were slightly lower when the topical formulation was applied with condom use compared to without condom use. However, given the high interparticipant variability in systemic exposure across all topical groups, these differences are unlikely to be clinically meaningful and are within the range expected from normal interparticipant variability in topical absorption. Condom use also resulted in slightly lower rather than higher systemic bioavailability compared to no-condom application at the same dose, a finding that is counterintuitive but should be interpreted with caution. Given the high interparticipant variability in systemic exposure across all topical groups, with coefficient of variation values for Cmax ranging from 36% to 77%, these differences are unlikely to be clinically meaningful and are within the range expected from normal interparticipant variability in topical absorption. No firm mechanistic conclusions regarding the effect of condom application on penile skin absorption can be drawn from this dataset. The delayed systemic Tmax observed after topical application, ranging from 12.58 to 15.67 hours, vs 1 hour with oral sildenafil, may reflect the prolonged absorption of sildenafil from the penile skin depot into systemic circulation, and should not necessarily be interpreted as a delay in local drug delivery to the penile vasculature. Although penile tissue concentrations of sildenafil were not assayed directly, previous PK data from vaginal vs oral dosing of drugs11,12support that local genital tissue concentrations peak within hours of local genital tract dosing, preceding the Tmax of plasma concentrations, due to local absorption. As this was a safety and pharmacokinetic study conducted in healthy men not requiring treatment for ED, no efficacy assessments were performed, and the relationship between systemic PK parameters and erectile response was not evaluated. The favorable safety profile observed here in men is consistent with the rationale supporting non-oral drug delivery strategies used broadly across sexual medicine.13–15 The most common side effects of oral sildenafil citrate use for ED are headache, flushing, dyspepsia, abnormal vision, nasal congestion, back pain, myalgia, nausea, dizziness, and rash.3 This side effect profile is reflective of the several hundred-fold higher systemic exposure measured after oral dosing compared to topical application. The 71 mg sildenafil in 2 g of cream was chosen for the dosage in healthy women with FSAD and went on to be tested in a Phase 2b safety and efficacy study.5,6 The safety profile seen among healthy men in the present cohort was similar to that seen among healthy premenopausal women and their male sexual partners in the Phase 2b safety and efficacy study.6 Strengths of this study include that the PK and safety profiles of the topical sildenafil creams were compared to the oral dosing and that multiple exams were done post dosing to document safety and characterize the PK profile. Limitations of this study were that it was designed as parallel groups rather than a cross over design and no placebo cream was tested, as has been done in other studies. There were no efficacy data collected among this population of healthy men without ED. Although we performed plasma PK sampling, there were no local tissue PK assessments, or penile hemodynamic assessments, which limits our understanding of local tissue absorption of drug. This somewhat tempered however, by having an oral dosing referent group. However, these data support the safety of topical sildenafil among healthy men. The data also illustrate the bioavailability of topical vs oral sildenafil citrate and resulting TEAEs in a well-controlled population. These data suggest that topical sildenafil was safe and well tolerated among men, and support further clinical development of Sildenafil Cream, 3.6% as a potential first-in-category treatment for ED. Supplementary Material Contributor Information Katherine Cornell, Strategic Science & Technologies (SST) LLC, Cambridge, MA 02141, United States. Isabella Johnson, Daré Bioscience, San Diego, CA 92122, United States. Andrea Thurman, Daré Bioscience, San Diego, CA 92122, United States. David Friend, Daré Bioscience, San Diego, CA 92122, United States. Supplementary material Supplementary material is available at Sexual Medicine online Author contributions K.C.: Conceptualization, Methodology, Validation, Supervision, Project Administration, Resources. I.J.: Visualization, Writing—Review and Editing. A.T.: Visualization, Formal Analysis, Writing—Original Draft. D.F.: Visualization, Writing – Review and Editing. Funding Strategic Science & Technologies, LLC, Cambridge, MA, United States. Conflicts of interest K.C. is an employee of SST LLC. A.T., I.J., and D.F. are employees of Daré Bioscience. References Associated Data Supplementary Materials